Favipiravir and COVID-19: A Simplified Summary

被引：62
作者：
Ghasemnejad-Berenji, Morteza [1 ]
Pashapour, Sarvin [2 ]
机构：
[1] Urmia Univ Med Sci, Dept Pharmacol & Toxicol, Fac Pharm, Orumiyeh, Iran
[2] Urmia Univ Med Sci, Motahari Hosp, Dept Pediat, Fac Med, Orumiyeh, Iran
来源：
DRUG RESEARCH | 2021年 / 71卷 / 03期
关键词：
antiviral drugs; drug research; clinical trials; IN-VIVO ACTIVITIES; CLINICAL CHARACTERISTICS; T-705; FAVIPIRAVIR; VIRUS; VITRO; WUHAN;
D O I：
10.1055/a-1296-7935
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan, China, at the end of 2019 and then spread rapidly all over the world. However, there are no specific antiviral therapies for COVID-19, using the agents which approved or in development for other viral infections is one of the potentially quickest ways to find treatment for this new viral infection. Favipiravir is an effective agent that acts as a nucleotide analog that selectively inhibits the viral RNA dependent RNA polymerase or causes lethal mutagenesis upon incorporation into the virus RNA. In view of recent studies and discussion on favipiravir, in this mini review we aimed to summarize the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19.
引用
收藏
页码：166 / 170
页数：5
相关论文
共 29 条
  • [11] Favipiravir (T-705), a novel viral RNA polymerase inhibitor
    Furuta, Yousuke
    Gowen, Brian B.
    Takahashi, Kazumi
    Shiraki, Kimiyasu
    Smee, Donald F.
    Barnard, Dale L.
    [J]. ANTIVIRAL RESEARCH, 2013, 100 (02) : 446 - 454
  • [12] In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections
    Gowen, Brian B.
    Wong, Min-Hui
    Jung, Kie-Hoon
    Sanders, Andrew B.
    Mendenhall, Michelle
    Bailey, Kevin W.
    Furuta, Yousuke
    Sidwell, Robert W.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (09) : 3168 - 3176
  • [13] The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase
    Jin, Zhinan
    Smith, Lucas K.
    Rajwanshi, Vivek K.
    Kim, Baek
    Deval, Jerome
    [J]. PLOS ONE, 2013, 8 (07):
  • [14] Lai CC., 2020, INT J ANTIMICROB AG, V55, DOI DOI 10.1016/J.IJANTIMICAG.2020.105924
  • [15] Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
    Li, Guangdi
    De Clercq, Erik
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (03) : 149 - 150
  • [16] Defining the Epidemiology of Covid-19-Studies Needed
    Lipsitch, Marc
    Swerdlow, David L.
    Finelli, Lyn
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (13) : 1194 - 1196
  • [17] T-705 (Favipiravir) Inhibition of Arenavirus Replication in Cell Culture
    Mendenhall, Michelle
    Russell, Andrew
    Juelich, Terry
    Messina, Emily L.
    Smee, Donald F.
    Freiberg, Alexander N.
    Holbrook, Michael R.
    Furuta, Yousuke
    de la Torre, Juan-Carlos
    Nunberg, Jack H.
    Gowen, Brian B.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (02) : 782 - 787
  • [18] Favipiravir: A New Medication for the Ebola Virus Disease Pandemic
    Nagata, Takashi
    Lefor, Alan K.
    Hasegawa, Manabu
    Ishii, Masami
    [J]. DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS, 2015, 9 (01) : 79 - 81
  • [19] Favipiravir (T-705) inhibits in vitro norovirus replication
    Rocha-Pereira, J.
    Jochmans, D.
    Dallmeier, K.
    Leyssen, P.
    Nascimento, M. S. J.
    Neyts, J.
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 424 (04) : 777 - 780
  • [20] The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset
    Safronetz, David
    Rosenke, Kyle
    Westover, Jonna B.
    Martellaro, Cynthia
    Okumura, Atsushi
    Furuta, Yousuke
    Geisbert, Joan
    Saturday, Greg
    Komeno, Takashi
    Geisbert, Thomas W.
    Feldmann, Heinz
    Gowen, Brian B.
    [J]. SCIENTIFIC REPORTS, 2015, 5
123